John A Bartlett

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Lack of protease inhibitor resistance following treatment failure--too good to be true?
    John A Bartlett
    Department of Medicine and the Duke Global Health Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 123:3704-5. 2013
  2. pmc Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings
    John A Bartlett
    Duke University Medical Center, Durham, NC 27710, USA
    AIDS 26:1345-54. 2012
  3. ncbi request reprint Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview
    John A Bartlett
    Duke University Medical Center, Durham, North Carolina 27710, USA
    HIV Clin Trials 8:221-6. 2007
  4. ncbi request reprint An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults
    John A Bartlett
    Duke University Medical Center, Durham, North Carolina 27710, USA
    AIDS 20:2051-64. 2006
  5. ncbi request reprint Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine
    John A Bartlett
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Acquir Immune Defic Syndr 43:284-92. 2006
  6. pmc Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania
    John A Crump
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Trop Med Int Health 16:830-7. 2011
  7. pmc Etiology of severe non-malaria febrile illness in Northern Tanzania: a prospective cohort study
    John A Crump
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    PLoS Negl Trop Dis 7:e2324. 2013
  8. pmc Characteristics of HIV voluntary counseling and testing clients before and during care and treatment scale-up in Moshi, Tanzania
    Meghan M Shorter
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Acquir Immune Defic Syndr 52:648-54. 2009
  9. pmc Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115
    Allan R Tenorio
    Department of Medicine, Rush Medical College, Rush University Medical Center, 600 S Paulina Street, Chicago, IL 60612, USA
    AIDS Res Hum Retroviruses 25:135-9. 2009
  10. ncbi request reprint Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection
    Albert M L Anderson
    Department of Medicine, Division of Infectious Diseases, Duke University Medical Centre, Durham, NC, USA
    Antivir Ther 12:1041-8. 2007

Research Grants

  1. ADULT AIDS CLINICAL TRIALS UNIT
    John Bartlett; Fiscal Year: 2006
  2. K24 MID-CAREER CLINICAL INVESTIGATOR AWARD
    John Bartlett; Fiscal Year: 2004
  3. HIV/AIDS Clinical Trials Unit
    John Bartlett; Fiscal Year: 2007
  4. International Clinical Trials Unit
    John Bartlett; Fiscal Year: 2007

Detail Information

Publications52

  1. doi request reprint Lack of protease inhibitor resistance following treatment failure--too good to be true?
    John A Bartlett
    Department of Medicine and the Duke Global Health Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 123:3704-5. 2013
    ..Genotypic resistance testing revealed only an M184V mutation associated with emtricitabine resistance. A decision regarding his next treatment regimen needs to be made...
  2. pmc Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings
    John A Bartlett
    Duke University Medical Center, Durham, NC 27710, USA
    AIDS 26:1345-54. 2012
    ..To evaluate virologic response rates of lopinavir/ritonavir (LPV/r) monotherapy as second-line antiretroviral treatment (ART) among adults in resource-limited settings (RLSs)...
  3. ncbi request reprint Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview
    John A Bartlett
    Duke University Medical Center, Durham, North Carolina 27710, USA
    HIV Clin Trials 8:221-6. 2007
    ..However, the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) components may also affect efficacy...
  4. ncbi request reprint An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults
    John A Bartlett
    Duke University Medical Center, Durham, North Carolina 27710, USA
    AIDS 20:2051-64. 2006
    ..To compare the effectiveness of three drug combination antiretroviral therapy (ART) in treatment-naive HIV-infected persons, and identify the predictors of responses...
  5. ncbi request reprint Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine
    John A Bartlett
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Acquir Immune Defic Syndr 43:284-92. 2006
    ..To compare alternative class-sparing antiretroviral regimens in treatment-naive subjects...
  6. pmc Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania
    John A Crump
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Trop Med Int Health 16:830-7. 2011
    ..To describe the contribution of paediatric HIV and of HIV co-infections to admissions to a hospital in Moshi, Tanzania, using contemporary laboratory methods...
  7. pmc Etiology of severe non-malaria febrile illness in Northern Tanzania: a prospective cohort study
    John A Crump
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    PLoS Negl Trop Dis 7:e2324. 2013
    ..In many areas, malaria is over-diagnosed, and patients without malaria have poor outcomes...
  8. pmc Characteristics of HIV voluntary counseling and testing clients before and during care and treatment scale-up in Moshi, Tanzania
    Meghan M Shorter
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Acquir Immune Defic Syndr 52:648-54. 2009
    ..We evaluated changes in characteristics of clients presenting for voluntary counseling and testing (VCT) before and during care and treatment center (CTC) scale-up activities in Moshi, Tanzania, between November 2003 and December 2007...
  9. pmc Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115
    Allan R Tenorio
    Department of Medicine, Rush Medical College, Rush University Medical Center, 600 S Paulina Street, Chicago, IL 60612, USA
    AIDS Res Hum Retroviruses 25:135-9. 2009
    ..Delaying a treatment switch in patients with partial virologic suppression and stable CD4+ T cells does not have profound effects on immune parameters...
  10. ncbi request reprint Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection
    Albert M L Anderson
    Department of Medicine, Division of Infectious Diseases, Duke University Medical Centre, Durham, NC, USA
    Antivir Ther 12:1041-8. 2007
    ..Suboptimal improvement in CD4+ T-cell count is not uncommon in HIV-infected patients with suppressed plasma HIV RNA levels, and a decrease in CD4+ T-cell count in patients with suppressed or low-level viraemia has been observed...
  11. ncbi request reprint A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
    ..Clinical stability has been observed with continued antiretroviral therapy (ART) in the setting of partial virological suppression. The optimal time to switch treatment in patients with low but detectable HIV-1 RNA is not known...
  12. doi request reprint Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study
    Susan D Emmett
    Duke University Medical Center, Durham, North Carolina, USA
    J Acquir Immune Defic Syndr 54:368-75. 2010
    ....
  13. ncbi request reprint Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons
    John A Bartlett
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    AIDS Res Hum Retroviruses 18:535-43. 2002
    ..We conclude that the addition of CTX to ART did not diminish the cellular reservoir in HIV-infected persons...
  14. ncbi request reprint Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature
    Albert M L Anderson
    Duke University Medical Center, Durham, NC 27710, USA
    Curr HIV/AIDS Rep 3:79-85. 2006
    ..In general, a lower switch threshold is recommended for patients during relapse on first or second line regimens...
  15. pmc Gender differences in the risk of HIV infection among persons reporting abstinence, monogamy, and multiple sexual partners in northern Tanzania
    Keren Z Landman
    Duke University Medical Center, Durham, North Carolina, USA
    PLoS ONE 3:e3075. 2008
    ..We examined the association between the number of sexual partners and the risk of HIV seropositivity among men and women presenting for HIV voluntary counseling and testing (VCT) in northern Tanzania...
  16. pmc Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study
    John A Crump
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Infect Dis 55:242-50. 2012
    ....
  17. pmc Brucellosis among hospitalized febrile patients in northern Tanzania
    Andrew J Bouley
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Trop Med Hyg 87:1105-11. 2012
    ..Brucellosis is an underdiagnosed and untreated cause of febrile disease among hospitalized adult and pediatric patients in northern Tanzania...
  18. pmc Effect of trimethoprim-sulfamethoxazole prophylaxis on antimicrobial resistance of fecal Escherichia coli in HIV-infected patients in Tanzania
    Susan C Morpeth
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Acquir Immune Defic Syndr 47:585-91. 2008
    ..Trimethoprim-sulfamethoxazole (SXT) reduces morbidity and mortality among HIV-infected persons in Africa, but its impact on antimicrobial resistance is of concern...
  19. ncbi request reprint Antiretroviral treatment literacy among HIV voluntary counseling and testing clients in Moshi, Tanzania, 2003 to 2005
    Keren Z Landman
    Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Int Assoc Physicians AIDS Care (Chic) 6:24-6. 2007
    ..Previous HIV testing was protective against low antiretroviral treatment literacy. These results support refocusing HIV education efforts and increasing synergy between HIV prevention and treatment programs...
  20. doi request reprint A randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern Tanzania
    Elizabeth A Reddy
    Duke University Medical Center, Durham, NC, USA
    BMC Infect Dis 14:89. 2014
    ..This study sought to determine the impact of providing mycobacterial culture results over standard of care [unconcentrated acid-fast (AFB) smears] on management of persons with suspected tuberculosis...
  21. ncbi request reprint Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection
    Thomas H Alexander
    Duke University Medical Center, Durham, NC 27705, USA
    J Acquir Immune Defic Syndr 34:475-81. 2003
    ..These results suggest that interruptions should be avoided whenever possible in patients on HAART with high plasma HIV-1 RNA set-points...
  22. ncbi request reprint Detection of minor drug-resistant populations by parallel allele-specific sequencing
    Fangping Cai
    Duke Human Vaccine Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nat Methods 4:123-5. 2007
    ..This assay may serve as a useful tool to study drug resistance in HIV and other infectious agents...
  23. pmc A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan Africa
    Richard C Waters
    Duke Global Health Institute, Duke University, Durham, NC 27701, USA
    J Acquir Immune Defic Syndr 56:443-52. 2011
    ..Guidelines in sub-Saharan Africa on when HIV-seronegative persons should retest range from never to annually for lower-risk populations and from annually to every 3 months for high-risk populations...
  24. ncbi request reprint Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function
    Gregory D Sempowski
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Immunol 25:462-72. 2005
    ....
  25. pmc Chikungunya and dengue fever among hospitalized febrile patients in northern Tanzania
    Julian T Hertz
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Am J Trop Med Hyg 86:171-7. 2012
    ..5, P = 0.007). CHIKV infection is an important but unrecognized cause of febrile illness in northern Tanzania. DENV or other closely related flaviviruses are likely also circulating...
  26. ncbi request reprint Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview
    John A Bartlett
    AIDS Research and Treatment Center, Duke University Medical Center, Durham, NC, USA
    J Acquir Immune Defic Syndr 41:323-31. 2006
    ..To identify optimal first-line therapies based on the rate of virologic success (VS) and the preservation of future treatment options in antiretroviral therapy (ART)-naive subjects...
  27. pmc Leptospirosis among hospitalized febrile patients in northern Tanzania
    Holly M Biggs
    Department of Medicine and Department of Pathology, Duke University Medical Center, Durham, NC, USA
    Am J Trop Med Hyg 85:275-81. 2011
    ..001). Among those with confirmed leptospirosis, the predominant reactive serogroups were Mini and Australis. Leptospirosis is a major yet underdiagnosed cause of febrile illness in northern Tanzania, where it appears to be endemic...
  28. ncbi request reprint Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population
    Susan C Morpeth
    Duke University Medical Center, Durham, North Carolina, 27710, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
    AIDS Res Hum Retroviruses 23:1230-6. 2007
    ....
  29. pmc Q fever, spotted fever group, and typhus group rickettsioses among hospitalized febrile patients in northern Tanzania
    Malavika Prabhu
    Department of Medicine, Division of Infectious Diseases and International Health, Duke University Medical Center, Duke University, Durham, North Carolina 27710, USA
    Clin Infect Dis 53:e8-15. 2011
    ....
  30. doi request reprint Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries
    John A Bartlett
    Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, USA
    Lancet Infect Dis 9:637-49. 2009
    ..There is also a need for more randomised controlled studies to identify the long-term outcomes, cost-effectiveness of ART, and use of virological monitoring in LMICs...
  31. pmc Invasive disease caused by nontuberculous mycobacteria, Tanzania
    John A Crump
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Emerg Infect Dis 15:53-5. 2009
    ..avium complex sequevar MAC-D. Invasive NTM disease is present in HIV-infected patients in sub-Saharan Africa...
  32. pmc Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania
    John A Crump
    Division of Infectious Diseases and International Health, Department ofMedicine, Duke University Medical Center, Box 102359, Durham, NC 27710, USA
    Clin Infect Dis 52:341-8. 2011
    ..few studies describe patterns of human immunodeficiency virus (HIV) co-infections in African hospitals in the antiretroviral therapy (ART) era...
  33. ncbi request reprint Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection
    Albert M L Anderson
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Expert Rev Anti Infect Ther 3:871-83. 2005
    ..Fixed dose combination abacavir/lamivudine should be considered as a viable treatment option for HIV-infected patients, particularly for those who have otherwise limited nucleoside reverse transcriptase inhibitor choices...
  34. ncbi request reprint Predictors of proteinuria and renal failure among women with HIV infection
    Lynda Anne Szczech
    Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Kidney Int 61:195-202. 2002
    ..This study examines the risk factors for proteinuria and renal failure in a large cohort of HIV-infected women not selected for the presence of renal disease...
  35. doi request reprint Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysis
    Ann M Buchanan
    Kilimanjaro Christian Medical Centre, Moshi, Tanzania Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, United States of America Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America
    PLoS ONE 9:e88679. 2014
    ..Early infant diagnosis of HIV-1 using dried blood spot (DBS) PCR among exposed infants provides an opportunity to assess current MTCT rates...
  36. pmc Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region
    Ann M Buchanan
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    Trop Med Int Health 15:1011-21. 2010
    ..To determine the normal haematological and immunological reference intervals for healthy Tanzanian children...
  37. ncbi request reprint Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12
    Beverly E Sha
    Department of Medicine, Section of Infectious Diseases, Rush Medical College, Chicago, IL, USA
    AIDS 18:1203-6. 2004
    ..Three responders had received IL-12, suggesting a possible adjuvant effect of Il-12. Transient mild injection site reactions (7.9) and systemic symptoms (3/9) occurred...
  38. ncbi request reprint A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
    Sarah A Myers
    Duke University Medical Center, Durham, NC, USA
    Antivir Ther 11:935-9. 2006
    ..However, local injection site reactions (ISR) occur in the majority of patients. The aim of this study was to determine the pathogenesis of ISRs...
  39. pmc Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities
    Sarah M Lofgren
    Department of Medicine, Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, North Carolina, USA
    AIDS 23:2459-66. 2009
    ..To assess technical and operational performance of a dried blood spot (DBS)-based HIV-1 RNA service for remote healthcare facilities in a low-income country...
  40. pmc Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania
    Nathan M Thielman
    Division of Infectious Diseases and International Health, Duke University Medical Center, Box 3867, Durham, NC 27701, USA
    Am J Public Health 96:114-9. 2006
    ..We evaluated the cost-effectiveness of fee-based and free testing strategies at an HIV voluntary counseling and testing (VCT) program integrated into a community-based AIDS service organization in Moshi, Tanzania...
  41. ncbi request reprint HIV infection: treatment outcomes in older and younger adults
    Melissa Fair Wellons
    School of Medicine, Department of Medicine, Center for Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Geriatr Soc 50:603-7. 2002
    ..To determine the effect of antiretroviral therapy (ART) on the immunological and virological outcomes of older human immunodeficiency virus (HIV)-infected patients compared with younger HIV-infected patients...
  42. ncbi request reprint Generic and branded drugs for the treatment of people living with HIV/AIDS
    John A Bartlett
    Division of Infectious Disease and International Health, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Int Assoc Physicians AIDS Care (Chic) 6:15-23. 2007
    ..Generic drugs have the potential to cause harm if rigorous standards for their use are not followed, but those that are qualified offer great promise in the treatment of HIV/AIDS...
  43. doi request reprint Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings
    John A Bartlett
    Department of Medicine, Duke University Medical Center, USA
    J Int Assoc Physicians AIDS Care (Chic) 8:253-68. 2009
    ..An understanding of these obstacles and suggested methods to overcome them must be addressed by global policy makers before universal ART access can be achieved...
  44. ncbi request reprint Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation
    Joseph J Eron
    AIDS Clinical Research Unit, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Acquir Immune Defic Syndr 37:1581-3. 2004
    ..Nucleoside analogue reverse transcriptase inhibitors may have continued ARV activity despite long durations of partially suppressive therapy and the presence of resistant HIV-1...
  45. ncbi request reprint Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration
    David W Haas
    Microbiology and Immunology, Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Clin Infect Dis 43:783-6. 2006
    ..Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016)...
  46. ncbi request reprint Antiretroviral rounds. A communication conundrum
    Keith Henry
    AIDS Clin Care 17:115-6. 2005
  47. ncbi request reprint Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions
    Becky Schweighardt
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, USA
    AIDS 16:2342-4. 2002
    ..We concluded that the repeated abrupt termination and resumption of certain antiretroviral drug regimens during STI therapy may lead to the development of drug resistance in chronically HIV-infected individuals...
  48. ncbi request reprint Early intensification with abacavir in subjects at high risk for incomplete viral suppression
    John A Bartlett
    Antivir Ther 8:361-3. 2003
  49. ncbi request reprint Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV
    Joseph J Eron
    Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Infect Dis 189:1075-83. 2004
    ..43 to -0.05 log(10) copies/mL) for the lowest dose to -1.96 log(10) copies/mL (95% CI, -2.02 to -1.37 copies/mL) for the highest dose. These results indicate that T-1249 is a potent new therapeutic agent for HIV-1 infection...
  50. ncbi request reprint Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects
    Ian Sanne
    Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    J Infect Dis 191:825-9. 2005
    ..The use of nevirapine in female patients with a low BMI should be discouraged...
  51. ncbi request reprint Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania
    Habib O Ramadhani
    Kilimanjaro Christian Medical Centre, Tumaini University, Moshi, Tanzania
    Clin Infect Dis 45:1492-8. 2007
    ..Access to antiretroviral therapy is rapidly expanding in sub-Saharan Africa. Identifying the predictors of incomplete adherence, virologic failure, and antiviral drug resistance is essential to achieving long-term success...
  52. ncbi request reprint Definition of proteinuria among women with HIV infection
    Lynda Anne Szczech
    Kidney Int 65:1519. 2004

Research Grants5

  1. ADULT AIDS CLINICAL TRIALS UNIT
    John Bartlett; Fiscal Year: 2006
    ..The applicants anticipate that Duke will continue as an efficient, cost-effective ACTU that contributes to the ACTG scientific agenda. ..
  2. K24 MID-CAREER CLINICAL INVESTIGATOR AWARD
    John Bartlett; Fiscal Year: 2004
    ..These mentorship activities are strongly supported by leadership of the Department of Medicine and the Division of Infectious Diseases, and an AIDS Training Grant, which provides financial support for young investigators. ..
  3. HIV/AIDS Clinical Trials Unit
    John Bartlett; Fiscal Year: 2007
    ..administrative component ..
  4. International Clinical Trials Unit
    John Bartlett; Fiscal Year: 2007
    ....